First‐in‐human, randomized, double‐blind, placebo‐controlled, dose escalation trial of the anti‐herpes simplex virus monoclonal antibody <scp>HDIT101</scp> in healthy volunteers-Reference-Cited by-同舟云学术

First‐in‐human, randomized, double‐blind, placebo‐controlled, dose escalation trial of the anti‐herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers

Published:2022-07-23 Issue:10 Volume:15 Page:2366-2377
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Blank Antje¹^ORCID,Hohmann Nicolas²,Dettmer Marlen²,Manka‐Stuhlik Anette²,Mikus Gerd¹,Stoll Felicitas¹,Stützle‐Schnetz Marlies¹,Thomas Daniel³,Exner Evelyn³,Schmitt‐Bormann Beate⁴,Schaller Torsten³,Laage Rico³,Schönborn‐Kellenberger Oliver⁵,Arndt Michaela³,Haefeli Walter E.¹^ORCID,Krauss Jürgen²

Affiliation:

1. Department of Clinical Pharmacology and Pharmacoepidemiology Heidelberg University Hospital Heidelberg Germany

2. NCT, National Center for Tumor Diseases, Department of Medical Oncology Heidelberg University Hospital Heidelberg Germany

3. Heidelberg ImmunoTherapeutics GmbH Heidelberg Germany

4. Medical Consulting Services Pfungstadt Germany

5. Cogitars GmbH Heidelberg Germany

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13365

Reference21 articles.

1. Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer;Glenny AM;Cochrane Database Systematic Rev,2009

2. Neonatal Skin Emergencies

3. World Health Organization.Herpes simplex virus Fact Sheet;2020.https://www.who.int/news‐room/fact‐sheets/detail/herpes‐simplex‐virus. Accessed April 4 2022.

4. Herpes simplex virus: global infection prevalence and incidence estimates, 2016

5. Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a highly effective combination monoclonal antibody therapy against Herpes simplex virus;Journal of Biomedical Science;2024-05-28

2. Innovations in monoclonal antibody-based multipurpose prevention technology (MPT) for the prevention of sexually transmitted infections and unintended pregnancy;Frontiers in Reproductive Health;2024-01-09

3. A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults;Journal of Clinical Immunology;2023-12-22

4. Safety and Efficacy of Single HDIT101 Infusion Versus Episodic Valacyclovir Standard-of-Care in Patients with Chronic Recurrent Anogenital Herpes Simplex Virus 2 (HSV-2) Infection: A Multicentre, Parallel-Group Design, Randomised, Double-Blind, Double-Dummy Phase 2 Trial;2023